The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 83 (high attention) · dilution pressure high · listing risk low · governance risk low · runway 0.6 mo · strongest signal: Runway < 6 months (Jun 30, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going concern in 8-k, runway < 6 months) coexists with live selling machinery (convertible note, pipe). Base case is a discounted raise; the question is when, not if.
Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Jul 27, 2026 | ▼ Convertible note | “convertible note” language in 8-K/A (EX-99.2) filed 2026-07-27 filing | 42 |
| Jul 27, 2026 | ▼ PIPE | “pipe” language in 8-K/A (EX-99.2) filed 2026-07-27 filing | 36 |
| Jul 27, 2026 | ▼ Reverse split | “reverse split” language in 8-K/A (EX-99.2) filed 2026-07-27 filing | 32 |
| Jul 27, 2026 | ▼ Going concern in 8-K | “going concern 8k” language in 8-K/A (EX-99.1) filed 2026-07-27 filing | 31 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~0.6 months runway: liquidity $492,000 as of 2026-06-30, burn $10,481,583/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 50 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 1,281,009 (2026-05-12) -> 14,008,209 (2026-08-13), +994% filing | 45 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $492,000 vs current liabilities $11,037,000 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →